[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Kylonova (Xiamen) Biopharma co., LTD.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100618147",false,"NCT07327840","Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a)","A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy and Safety of Kylo-11 in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)","Inclusion Criteria:\n\n* Age 18 to 80 years\n* Clinical diagnosis of atherosclerotic cardiovascular disease with elevated Lp(a)\n* Other inclusion criteria applied per protocol.\n\nExclusion Criteria:\n\n* Have moderate to severe heart failure (New York Heart Association \\[NYHA\\] Functional Classification III or IV during Screening) or last known left ventricular ejection fraction \\\u003C30%\n* Have uncontrolled hypertension (systolic blood pressure \\[SBP\\] ≥160 mmHg or diastolic blood pressure \\[DBP\\] ≥100 mmHg)\n* Have uncontrolled cardiac arrhythmia defined as recurrent and highly symptomatic ventricular tachycardia, atrial fibrillation with rapid ventricular response, or supraventricular tachycardia that are not controlled by medications, in the past 3 months prior to randomization\n* Have had any malignancy within 5 years prior to randomization (except for non-melanoma skin cancers, cervical in-situ carcinoma, breast ductal carcinoma in situ, or stage 1 prostate carcinoma that has been successfully treated)\n* Other exclusion criteria applied per protocol.","ALL","18 Years","80 Years",{"count":19,"type":20},204,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This is a phase 2, double-blind, randomized, placebo-controlled, multi-center, dose-finding study to evaluate the efficacy and safety of Kylo-11 administered subcutaneously compared to placebo in participants with ASCVD and elevated Lp(a).",[26],"Lipoprotein Disorder","RECRUITING","2026-06-23",{"date":30,"type":31},"2026-06-25","ACTUAL",{"date":33,"type":31},"2025-10-29",{"date":35,"type":20},"2028-08-31",{"name":37,"class":38},"Kylonova (Xiamen) Biopharma co., LTD.","INDUSTRY",59,""]